Titlebook: Neurodegenerative Disorders; A Clinical Guide Orla Hardiman,Colin P. Doherty,Peter Bede Book 2016Latest edition Springer International Publ

只看該作者 · 發(fā)表于 2025-3-30 16:52:12

David Oliver,Sinead Maguire,Orla Hardiman,Peter Bede

只看該作者 · 發(fā)表于 2025-3-30 22:36:22

只看該作者 · 發(fā)表于 2025-3-31 01:27:38

Dementia and Cerebrovascular Disease, from dementia onset to death is 3.9 years for patients with VaD, as compared with 7.1 years for patients with AD. There are currently no established biochemical markers for VaD; and currently MR changes of ischaemia are the most widely used biomarker. Modifiable risk factors for VaD are those that

只看該作者 · 發(fā)表于 2025-3-31 08:57:06

只看該作者 · 發(fā)表于 2025-3-31 09:45:01

Neuroinflammatory Disorders,, disease progression, and MS subtypes are being developed..As the disease progressses the majority of MS patients develop irreversible disability due to axonal loss. To date no DMT has been proven to alter the course of the progressive phase of the disease. However, recent advances in glial biology

只看該作者 · 發(fā)表于 2025-3-31 17:03:47

只看該作者 · 發(fā)表于 2025-3-31 20:01:59

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評(píng)	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 13:35
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved